Ctrl

K

Albuterol

Oral
Inhalation
Class
Bronchodilators
Subclass
Short-acting beta-agonists
Substance name
Albuterol sulfate, salbutamol
Brand names
Ventolin HFA®, Proair HFA®, Proair RespiClick®, Proventil HFA®
Common formulations
Inhalation solution
Dosage and administration
Adults patients
Symptomatic relief of bronchospasm in patients with reversible obstructive airway disease
•
Maintenance: 2-4 mg PO q6-8h (tablets or syrup)
•
Maximum: 32 mg per day
Indications for use
Labeled indications
Adults
•
Symptomatic relief of bronchospasm in patients with reversible obstructive airway disease
Safety risks
Contraindications
Hypersensitivity to albuterol or its components
Warnings and precautions
Asthma exacerbation
•
Maintain a high level of suspicion, as asthma may deteriorate acutely over a period of hours or chronically over several days or longer. Consider initiating combination therapy for adequate control of asthma.
Cardiovascular adverse events
•
Use extreme caution in patients taking MAOIs or TCAs or within 2 weeks of discontinuation.
•
Use caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
•
Use caution in patients taking other sympathomimetic agents.
Decreased drug efficacy
•
Use caution in patients taking β-blockers.
Decreased serum potassium
•
Maintain a high level of suspicion, as β-agonists may cause significant hypokalemia. Use caution in patients taking non‑potassium-sparing diuretics. Consider monitoring potassium levels.
Drug hypersensitivity reaction
•
Maintain a high level of suspicion, as hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema, may occur after the administration of albuterol.
Paradoxical bronchospasm
•
Maintain a high level of suspicion, as life-threatening paradoxical bronchospasm may occur after administration. Discontinue immediately if paradoxical bronchospasm occurs.
Sympathomimetic adverse effects
•
Use caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
No guidance available.
Renal replacement therapy
Any modality
•
No guidance available.
Hepatic impairment
Any severity
•
No guidance available.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: A, A
•
Use only if benefits outweigh potential risks. Evidence of fetal harm in animals.
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Nervousness, tremor
Common 1-10%
•
Dizziness, headache, insomnia, weakness, nausea, hyperactivity, muscle cramps, ↑ appetite, nosebleed, palpitations, tachycardia
Uncommon < 1%
•
Somnolence, restlessness, irritability, chest discomfort, skin flushing, dysuria, mydriasis, hyperhidrosis, chest pain, epigastric pain, cough
Rare < 0.1%
•
Urticaria, skin rash, angioedema, bronchospasm, oropharyngeal edema
Unknown frequency
•
Hypertension, vomiting, change in taste, vertigo, dry mouth
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource